GBP100.08
0.39% today
London, Nov 21, 01:45 pm CET
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

AstraZeneca Stock price

GBP99.69
-19.61 16.44% 1M
-20.53 17.08% 6M
-4.03 3.89% YTD
+0.80 0.81% 1Y
+20.63 26.10% 3Y
+35.43 55.13% 5Y
+65.78 193.98% 10Y
London, Closing price Wed, Nov 20 2024
-0.55 0.55%
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

Key metrics

Market capitalization GBP154.55b
Enterprise Value GBP174.47b
P/E (TTM) P/E ratio 30.18
EV/FCF (TTM) EV/FCF 22.27
EV/Sales (TTM) EV/Sales 4.32
P/S ratio (TTM) P/S ratio 3.83
P/B ratio (TTM) P/B ratio 5.09
Dividend yield 2.29%
Last dividend (FY23) GBP2.28
Revenue growth (TTM) Revenue growth 10.00%
Revenue (TTM) Revenue GBP40.38b
EBIT (operating result TTM) EBIT GBP7.99b
Free Cash Flow (TTM) Free Cash Flow GBP7.83b
Cash position GBP3.68b
EPS (TTM) EPS GBP3.30
P/E forward 23.18
P/S forward 3.69
EV/Sales forward 4.16
Show more

Create a Free Account to create an AstraZeneca alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

AstraZeneca Stock Analysis

Analyst Opinions

29 Analysts have issued a AstraZeneca forecast:

23x Buy
79%
6x Hold
21%

Analyst Opinions

29 Analysts have issued a AstraZeneca forecast:

Buy
79%
Hold
21%

Financial data from AstraZeneca

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
40,380 40,380
10% 10%
100%
- Direct Costs 10,644 10,644
0% 0%
26%
29,736 29,736
14% 14%
74%
- Selling and Administrative Expenses 8,157 8,157
9% 9%
20%
- Research and Development Expense 9,119 9,119
13% 13%
23%
12,460 12,460
19% 19%
31%
- Depreciation and Amortization 4,471 4,471
1% 1%
11%
EBIT (Operating Income) EBIT 7,989 7,989
34% 34%
20%
Net Profit 5,119 5,119
7% 7%
13%

In millions GBP.

Don't miss a Thing! We will send you all news about AstraZeneca directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AstraZeneca Stock News

Positive
The Motley Fool
about 3 hours ago
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
Neutral
Business Wire
one day ago
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative to improve access, affordability and outcomes for patients in urban, suburban and rural communities. This brings the total contributions from the program to more than $15 million to date. Now in its fourth ...
Negative
Proactive Investors
one day ago
AstraZeneca PLC (LSE:AZN) and Daiichi Sankyo said they are 'disappointed and disagree' with a decision by the UK medicines regulator not to give the green light to a breast cancer drug they jointly developed. Talks to approve Enhertu for NHS used collapsed over pricing and despite the intervention of Wes Streeting, the health secretary.
More AstraZeneca News

Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Pascal Soriot
Employees 89,900
Founded 1992
Website www.astrazeneca.co.uk

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today